Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation by Caliò, Anna et al.
Oncotarget54096www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 33), pp: 54096-54105
Distinct clinicopathological features in metanephric adenoma 
harboring BRAF mutation
Anna Caliò1,2, John N. Eble1, Ondrej Hes3, Guido Martignoni2,4, Saul E. Harari1, 
Sean R. Williamson5, Matteo Brunelli2, Adeboye O. Osunkoya6, Lisha Wang7, Eva 
Comperat8, Antonio Lopez-Beltran9, Mingsheng Wang1, Shaobo Zhang1, Kendra L. 
Curless1, Kristin M. Post1, Hsim-Yee Chang1, Claudio Luchini1,2, Lee Ann Baldrige1, 
Gregory T. MacLennan10, Rodolfo Montironi11, David J. Grignon1 and Liang Cheng1
 1Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
 2Department of Pathology, University of Verona, Verona, Italy
 3Department of Pathology, Charles University Hospital Plzeň, Pilsen, Czech Republic
 4Department of Pathology, Pederzoli Hospital, Peschiera, Italy
 5Department of Pathology and Laboratory Medicine, Henry Ford Health System, Detroit, Michigan, USA
 6Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA
 7Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan, USA
 8Department of Pathology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
 9 Unit of Anatomical Pathology, Department of Surgery, Faculty of Medicine, Cordoba, Spain and Champalimaud Clinical 
Center, Lisbon, Portugal
10Departments of Pathology and Laboratory Medicine, Case Western Reserve University, Cleveland, Ohio, USA
11 Department of Pathological Anatomy and Histopathology, School of Medicine, Polytechnic University of The Marche Region 
(Ancona), Ancona, Italy
Correspondence to: Liang Cheng, email: liang_cheng@yahoo.com
Keywords: kidney, metanephric adenoma, BRAF, nephroblastoma/Wilms tumor, immunohistochemistry
Received: March 08, 2016     Accepted: July 07, 2016     Published: August 08, 2016
Copyright: Caliò et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source 
are credited.
ABSTRACT
BRAF mutation recently has been reported in metanephric adenoma. We sought 
to determine the clinical and morphologic features of BRAF-mutated metanephric 
adenoma and to correlate BRAF mutation with BRAF V600E immunohistochemical 
staining results. A series of 48 metanephric adenomas and 15 epithelial-predominant 
nephroblastomas were analyzed for the occurrence of BRAF mutation (BRAF V600E/
V600E complex, BRAF V600D, BRAF V600K and BRAF V600R) using the BRAF RGQ 
PCR kit (Qiagen). Immunohistochemistry was performed using monoclonal mouse 
antibodies against p16INK4 and VE1 (Spring Bioscience), recognizing the BRAF V600E 
mutant protein. Forty-one of 48 cases (85%) showed BRAF V600E mutation; none of 
the other BRAF variants was detected. Of 41 BRAF-mutated metanephric adenomas, 
33 showed positive VE1 immunostaining (sensitivity 80%, specificity 100%); in 
all cases we detected p16INK4 expression regardless of BRAF mutation status. All 
epithelial-predominant nephroblastomas were BRAF-wild-type and none expressed 
VE1. The following features were associated with BRAF V600E mutation: older patients 
(p=0.01), female predominance (p=0.005) and the presence of a predominantly acinar 
architecture (p=0.003). In summary, BRAF-mutated metanephric adenomas were 
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associated with older age, female predominance, and the presence of a predominant 
acinar component. A subset (20%) of BRAF-mutated metanephric adenomas was not 
detected by VE1 immunostaining.
INTRODUCTION
Metanephric adenoma of the kidney is an uncommon 
benign neoplasm which is usually asymptomatic and 
discovered incidentally. These tumors mostly occur in 
middle-aged individuals, with a female predominance 
(2:1), although the age distribution is broad, ranging 
from children to the elderly [1–4]. On gross examination, 
metanephric adenomas are typically circumscribed, 
not-encapsulated, solid masses. Histologically, these 
neoplasms are typically composed of small epithelial 
cells arranged as tightly packed small acini. A hyalinized 
or edematous stroma is present occasionally. Psammoma 
bodies are common. The cells have scant cytoplasm, 
round nuclei, and variably-present nuclear grooves. 
However, metanephric adenomas may assume a variety of 
architectures and may thus present a diagnostic challenge 
to the pathologist. The main differential diagnostic 
considerations for metanephric adenoma are epithelial-
predominant nephroblastoma in children and the solid 
variant of papillary renal cell carcinoma in adults. In 
challenging cases, immunohistochemistry and FISH 
techniques are helpful. With immunohistochemistry, 
metanephric adenomas usually label for WT1 and CD57 
and are characteristically negative for CK7 and AMACR 
[5]. FISH can be used for analyzing chromosomes 7, 
17 and Y. Metanephric adenoma lacks the gains of 
chromosome 7 and 17 and losses of Y that are typical of 
papillary renal cell carcinoma [6].
Recently, somatic mutation of the BRAF (v-raf 
murine sarcoma viral oncogene homolog B1) oncogene, 
located on the long arm of chromosome 7, was identified 
as a common event in metanephric adenomas [7–12]. 
BRAF is a serine/threonine kinase that plays a critical 
role in the mitogen-activated protein kinase (MAPK) 
signaling pathway. The V600E mutation, which accounts 
for the vast majority of BRAF alterations, induces 
phosphorylation of downstream targets leading to 
constitutive activation of the cascade. The same mutation 
has been implicated in the development of many tumors, 
including melanocytic nevi [13] and melanoma [14], 
papillary thyroid carcinoma [15], pilocytic astrocytoma 
[16], colonic adenocarcinoma [17], cholangiocarcinoma 
[18], borderline ovarian cancer [19], pulmonary 
adenocarcinoma [20], Langerhans cell histiocytosis [21] 
and hairy cell leukemia [22]. Of note, immunostaining 
with the VE1 antibody has been reported as reliable 
for the detection of BRAF V600E mutation in several 
of the above-mentioned neoplasms [23–29]. Regarding 
metanephric adenomas, only a few studies [8, 9, 11] 
containing overall only 20 cases, have investigated the 
use of immunohistochemistry to detect BRAF mutation.
In this study, we correlated BRAF mutation, 
detected by molecular analysis, with BRAF V600E 
immunohistochemical staining in a series of 48 
metanephric adenomas and 15 epithelial-predominant 
nephroblastomas. In addition, we sought to identify 
clinical and histopathological features of metanephric 
adenomas harboring BRAF mutation.
RESULTS
Of the 48 patients with metanephric adenoma, 31 
were female and 17 were male (F:M ratio, 1.8:1). The 
median age at diagnosis was 54 years (range: 5 to 84 years) 
and the median size of the tumor was 4 cm (range from 1.1 
to 8 cm) (Table 1). Among the 15 epithelial-predominant 
nephroblastoma patients, 8 were female and 7 were male 
(F:M ratio, 1.1:1). The median age was 5 years (range, 8 
weeks to 41 years). There were 3 tumors that occurred 
in adult patients (27, 35, and 41 years, respectively), one 
female and two male (Table 2).
Microscopic examination of metanephric adenomas 
showed neoplasms composed of small, uniform and 
overlapping epithelial cells with scant cytoplasm, 
inconspicuous nucleoli and essentially no mitotic figures. 
These cells were arranged in a variety of architectural 
patterns (Figure 1). Simple tubules, acini and solid 
patterns were the most common. Papillary structures 
were present in 14 cases (29%) and were the predominant 
pattern (>50% of the tumor) in 3. Glomeruloid bodies 
were present in 14 cases (29%), and branching tubules 
were present in 24 cases (50%). Eighteen cases (38%) 
showed a variably thickened and usually discontinuous 
fibrous pseudocapsule. Fibrous septa that gave a vaguely 
multinodular appearance were recognized in 14 cases 
(29%). Twenty-eight tumors (58%) contained psammoma 
bodies, ranging from isolated and scattered to numerous. 
A few foamy macrophages were seen in only 3 cases 
(6%). A stromal component was virtually absent in 4 
cases (8%). The remaining cases demonstrated edematous 
or hyalinized stroma or both (range from 5% to 40% of 
tumor volume).
BRAF V600E mutations were identified in 41 of 48 
cases (85%) and none of the other BRAF mutation variants 
was detected. Of these, 30 patients were women and 11 
were men (F:M, 2.7:1). The median age was 57 years 
(range from 5 to 84 years) and the greatest dimension 
ranged from 1.4 to 8 cm (median = 3.9 cm). Among 
the 7 BRAF-wild-type cases, there was a striking male 
predominance (F:M 1:6) (p=0.0055), and the patients 
tended to be younger (median 33, range from 10 to 74) 
(p=0.014). Tumor size in BRAF-wild-type cases (median 
= 3.5, range from 1.1 to 6.5) was similar to the BRAF-
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mutated cases (p=0.71). Most BRAF-mutated cases 
exhibited a predominantly acinar architecture (p=0.003). 
Among 5 cases without this unique histologic feature, 
4 were composed mostly of tubules and one mostly 
of papillae. The other morphological features were 
not associated with BRAF mutational status. None of 
epithelial-predominant nephroblastomas had BRAF 
mutation.
There was positive cytoplasmic immunolabeling for 
VE1 antibody in 33 of 41 (80%) metanephric adenomas 
with BRAF mutation (Figure 2). All VE1 immunostaining 
positive cases showed BRAF V600E mutation, detected 
by Qiagen BRAF RGQ PCR kit. No nuclear staining was 
detected in any case. All cases of epithelial-predominant 
nephroblastoma were completely negative, correlating 
with their BRAF wild-type status. Positive immunolabeling 
Table 1: Clinical and histopathological features of BRAF-mutated and BRAF-wild-type metanephric adenomas
Characteristic BRAF mutated BRAF wild type P value
Cases, n (%) 41 (85) 7 (15)  
Gender, n (%)    
 Male 11 (27) 6 (86)
0.0055
 Female 30 (73) 1 (14)
Age median 57 33 0.014
Size median 3.9 3.5 0.71
Architecture    
 Pseudocapsule 16 2 0.66
 Fibrous septa 12 2 0.99
Histologic pattern (range, %)*    
 Acini 36 (5-70) 4 (5-25) 0.003
 Solid areas 27 (5-100) 6 (5-50) 0.41
 Tubules 25 (5-60) 5 (10-50) 0.74
 Branching tubules 19 (5-40) 5 (5-20) 0.35
 Glomeruloid bodies 11 (5-40) 3 (15-30) 0.32
 Papillae 12 (5-80) 2 (20-35) 0.91
Stroma    
 Hyalinized 26 (5-40) 6 (5-15) 0.94
 Edematous 28 (5-30) 2 (15-20) 0.22
Other features    
 Psammoma bodies 22 6 0.11
 Foamy Histiocytes 3 0  
Immunohistochemistry    
 VE1 positive, n (%) 33 (80) 0  
 VE1 negative, n (%) 8 (20) 7 (100)  
 p16INK4 antibody, n (%)    
  5-≤20% 12 (29) 1 (14) 0.65
  >20% 29 (71) 6 (86)
*The numbers indicated cases BRAF mutated and BRAF wild-type with distinct histopathological characteristics. The range 
of area occupied by each histological pattern was reported as a percentage in parenthesis.
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for p16INK4 was detected in all metanephric adenomas 
(range from 5% to 100% of cells), which manifested as 
nuclear or cytoplasmic staining or both. On the other 
hand, p16INK4 immunostaining was demonstrated in 8 of 
15 (53%) epithelial-predominant nephroblastomas.
The histopathological characteristics, molecular and 
immunohistochemical results are detailed in Table 1 and 
in Table 2.
DISCUSSION
BRAF is an oncogene that normally functions as a 
regulator of cell division and differentiation through its 
role in the MAP kinase pathway. Mutations in this gene, 
which lead to constitutive activation of downstream 
signaling within this pathway, were most famously 
implicated in the development of melanoma [14]. Several 
specific pro-oncogenic mutations of BRAF have since been 
identified and implicated in the development of a variety 
of solid and hematopoietic neoplasms [14, 30–32]. The 
vast majority, however, are characterized by a thymine-
to-adenine transversion at exon 15, which results in an 
amino acid substitution of valine (V) for glutamic acid 
(E) at codon V600 (V600E) [14]. It is worth noting that 
clinical trials have recently emerged proposing targeted 
therapy for nonmelanoma cancers harboring BRAF 
mutations, demonstrating the important role of BRAF-
testing [33].
Attention to the association of BRAF mutation 
with metanephric adenoma has been drawn by a few case 
reports and small series [7, 8, 10, 11, 34]. The current 
study, which tested 48 cases of metanephric adenoma 
for BRAF mutation, is the largest of its kind. Molecular 
testing demonstrated that 85% of these tumors harbored 
a BRAF mutation; a number in line with the findings of 
Choueiri et al. [7], who described this mutation in 26 of 
29 cases (89%), but somewhat lower than the remaining 
cases in the literature, which cumulatively yielded a 
mutated BRAF in 22 of 24 cases (92%) (Table 3). All the 
BRAF-mutated cases in this study carried the same V600E 
mutation, which again is in keeping with the findings of 
almost all prior studies [7, 9-11, 34]. Of note, Udager et 
al. [8] identified BRAF V600D in 2 of 10 BRAF-mutated 
metanephric adenomas. The current study, which looked 
for the most common variants, including the V600D, did 
not find this or any other BRAF mutation variant. In this 
study we also provided clinical and morphologic features 
characteristic of each metanephric adenoma subset. We 
found that BRAF-mutated cases were associated with 
older age whereas BRAF wild-type metanephric adenomas 
presented earlier. Consistent with our findings, Choueiri 
et al. showed increased age (55 vs 33 years) in patients 
harboring a BRAF mutation [7]. A correlation between 
BRAF mutation status and tumor size has been proposed 
[7], though the current study did not show any size 
difference, a discrepancy that probably resulted from the 
Table 2: Clinical, molecular and immunohistochemical features of epithelial-predominant nephroblastoma
Case Gender Age (years) BRAF status VE1 p16
1 M 3 wild-type 0 30% +
2 F 8 weeks wild-type 0 0
3 F 27 wild-type 0 <5% +
4 F 3 wild-type 0 0
5 F 6 wild-type 0 30% +
6 F 5 wild-type 0 40% +
7 M 3 wild-type 0 0
8 M 2 wild-type 0 0
9 F 5 wild-type 0 0
10 M 41 wild-type 0 5-10% +
11 M 2 wild-type 0 100% +
12 F 5 wild-type 0 0
13 F 6 wild-type 0 0
14 M 12 wild-type 0 40-50% +
15 M 35 wild-type 0 10% +
M: male, F: female, 0: absence of staining.
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limited number of BRAF-wild-type cases presented in the 
prior study. With regards to gender, this is the first study to 
demonstrate a strong male predominance in metanephric 
adenomas that are BRAF wild-type. Other studies have 
shown BRAF mutation in 3 of 3 and 4 of 5 male subjects 
respectively [7, 8], however the present study, which 
included 17 males, is the largest to test for BRAF in a 
male cohort. Also, we included 4 pediatric cases (<12 
years old) in our series. As in adults, BRAF mutation has 
been reported in pediatric metanephric adenomas [11]. 
For the first time, we have outlined distinct morphological 
features characteristic of BRAF-mutated and BRAF-wild-
type metanephric adenomas. There was a predominance 
of acinar architecture (p=0.003) associated with BRAF-
mutated metanephric adenomas. The combination of solid 
architecture with psammoma bodies and background 
Figure 1: Histopathological features of metanephric adenoma. A. Acinar pattern. B. Solid-like area. C. Elongated tubules. D. 
Tubules with branching contours. E. Glomeruloid bodies. F. Papillary structures.
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hyalinized stroma was found to occur with greater 
frequency in BRAF-wild-type cases, but the difference did 
not reach statistical significance.
The presence of a specific and consistent mutation 
implies a potential role for immunohistochemistry, with 
the VE1 antibody, as a surrogate for molecular testing, 
particularly in instances where limited tissue is available 
or the molecular method for BRAF mutation detection is 
not accessible. Several studies have demonstrated excellent 
concordance between immunostaining and mutation status 
in a variety of other neoplasms [25–29]. In the current 
study, 33 of 41 BRAF-mutated cases were positive by 
immunohistochemistry. Despite it having been speculated 
that VE1 would be valuable diagnostically [9], this study 
demonstrated that VE1 antibody is a very specific (100%) 
but less sensitive (80%) marker for identifying BRAF-
mutated metanephric adenomas. Moreover, a subset 
(15%) of metanephric adenomas does not have BRAF 
mutation, prompting again careful use as a diagnostic 
tool. None of epithelial-predominant nephroblastomas 
was positive for BRAF mutation using either molecular or 
immunohistochemistry methods in current study. Previous 
investigations also found that nephroblastomas were 
negative for BRAF mutation by molecular assays [34, 35].
Another aspect of the BRAF V600E mutation is its 
ability to act not only as an oncogene, but paradoxically, 
to induce cellular senescence. This has been well studied 
and documented in various BRAF-driven neoplasms 
[36–41]. One of the major markers shown to identify 
BRAF-induced senescence is p16INK4 [36]. In light of 
the indolent clinical course and high frequency of BRAF 
mutation in metanephric adenomas, all cases were 
stained with the p16INK4 antibody. We found that every 
metanephric adenoma was positive for this marker. The 
fact that even BRAF-wild-type tumors also exhibited 
positive staining with p16INK4 suggests that mechanisms 
Figure 2: Molecular and immunohistochemical findings in metanephric adenoma. Metanephric adenoma predominantly 
composed of acini harboring BRAF mutation A. Detection of BRAF V600E/Ec mutation B. Fluorescence is detected during cycling for both 
the sample (purple) and sample control (blue). A ≤7.0 difference between the crossing threshold cycles is an acceptable cutoff for a positive 
V600E/Ec result. The calculated delta CT value of these samples (0.34) demonstrates the detection of V600E/Ec BRAF mutation in relation 
to the sample control. The same case showed a strong cytoplasmic positivity for BRAF VE1 staining C. and strong nuclear expression of 
p16INK4 immunolabeling D.
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for oncogene-induced senescence independent of BRAF 
mutation exist. In addition, approximately half of the 
epithelial-predominant nephroblastomas were positive 
for p16INK4, illustrating again that alternative modes of 
senescence induction may be involved. Interestingly, 
p16INK4 expression has been shown to correlate with 
good prognosis in nephroblastoma [42]. The mechanism 
by which some nephroblastomas evade the senescence 
pathways remains unknown [43].
In summary, we have identified distinct 
clinicopathologic patterns associated with BRAF-
mutated metanephric adenoma. These include older 
age, female predominance, and the presence of a 
prominent acinar component. A subset of BRAF-mutated 
metanephric adenomas (20%) was not detected by VE1 
immunostaining. p16INK4 immunostaining was uniformly 
positive in all metanephric adenomas.
MATERIALS AND METHODS
Patients and samples
Forty-eight cases of metanephric adenoma and 
fifteen cases of epithelial-predominant nephroblastoma 
were collected from participating institutions. For each 
case of metanephric adenoma, the following morphologic 
features were recorded: the presence or absence of a 
pseudocapsule, foamy histiocytes, and fibrous septa; 
the relative proportion of stroma and its being either 
edematous or hyalinized; the presence and quantity of 
psammoma bodies; and the architectural patterns. With 
respect to architecture, specific patterns were recognized 
including tubules with or without complex branching, 
acini, glomeruloid structures (short, rounded papillae 
projecting into small cysts), solid-like (tightly packed acini 
with overlapping nuclei), and papillary. When present, the 
proportion of the tumor made up of each of these patterns 
was recorded as a percentage. A pattern that was greater 
than 50% within the tumor was considered predominant. 
This research was approved by the Institutional Review 
Board.
Immunohistochemistry
Immunohistochemical analysis was performed on 
all cases utilizing the VE1 antibody, which recognizes 
the BRAF V600E mutant protein (Spring Bioscience, 
Pleasanton, CA, USA), on whole tissue sections. BRAF 
V600E-mutated melanoma tissue was stained concurrently 
to serve as a positive control. Cytoplasmic staining was 
scored as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ 
(strong) [25]. A positive result required both cytoplasmic 
staining in >10% of tumor cells and moderate to strong 
intensity, as previously described [44–46]. In addition, 
immunohistochemical staining for p16INK4 (CINtec®, 
Roche, Germany) was performed on whole sections for 
Table 3: Metanephric neoplasms harboring BRAF mutations: literature review













Choueiri et al., 
2012 29 54 (25-78) 26F 3M 2.7 (1.2-7) 26 (89%) V600E NA MA
Dadone et al., 
2013 1 61 F 3.5 1 (100%) V600E NA MA
Pinto et al., 
2015 6 52 6F 2.6 6 (100%) V600E 6 (100%) MA
Udager et al., 
2015 11 45 (16-84) 6F 5M 2.7 (1.3-5.1) 10 (91%)
V600E (8) 
V600D (2) 8 (88%) MA
Chami et al., 
2015 3 9 (4-10) 1F 2M NA (2-4.5) 2 (67%) V600E 2 (100%) MA
 1 4 1M 3.1 1 (100%) V600E 1 (100%) MAF
Mangray et al., 
2015 1 10 F 1.1 1 (100%) V600E 1 (100%) MAF
 3 NA NA NA 3 (100%) V600E NA MA
Current study 48 54 (5-84) 31F 17M 4 (1.1-8) 41 (85%) V600E 33 (80%) MA
MA metanephric adenoma; MAF metanephric adenofibroma; M male; F female; NA not available.
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each case, and the percentage of positive-staining tumor 
cells was recorded.
High resolution melting test for BRAF 
mutational analysis
The BRAF mutations were analyzed using real-
time PCR-high resolution melting test. Areas of tumor 
in each case designated for testing were circled on 
hematoxylin and eosin-stained slides by a pathologist 
(LC). The DNA extractions were run using the BRAF 
RGQ PCR Kit (Qiagen, Valencia, CA), designed to 
detect somatic mutations of the BRAF gene using real-
time polymerase chain reaction with the Rotor-Gene 
Q 5plex HRM instrument. DNA concentrations were 
analyzed by the NanoDrop ND-1000 Spectrophotometer 
(NanoDrop Technologies, Wilmington, DE). Using 
ARMS (Amplification Refractory Mutation System) 
and Scorpions technologies, the BRAF RGQ PCR Kit 
detects mutations at codon 600 of the BRAF oncogene 
against a background of wild type genomic DNA. The 
specific mutations detected by this assay are V600E/
V600E complex (V600E/Ec), V600D, V600K, and 
V600R. All procedures were performed according to the 
manufacturer’s protocol.
Statistical analysis
Fisher's exact test was used to compare categorical 
data for clinicopathologic characteristics between BRAF-
mutated and BRAF-wild-type subgroups and Student’s t 
test to compare continuous data. All P values were based 
on a two-sided hypothesis.
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